Related Experiment Videos
Improved cardiac performance during exercise following hydralazine treatment in chronic heart failure
Insights
Hydralazine improved cardiac index in heart failure patients. Long-term use shifted blood flow distribution, potentially enhancing muscle perfusion and reducing oxygen demand during exercise.
Area of Science:
- Cardiology
- Pharmacology
- Exercise Physiology
Background:
- Chronic heart failure (CHF) management often involves multiple medications.
- Optimizing hemodynamic function in CHF patients is crucial for improving outcomes.
- Hydralazine is a vasodilator with potential benefits in heart failure.
Purpose of the Study:
- To evaluate the acute and long-term hemodynamic effects of hydralazine in male patients with stable chronic heart failure.
- To assess changes in cardiac index, stroke volume, and arteriovenous oxygen difference during exercise.
Main Methods:
- Nine male patients with stable CHF, on digoxin and diuretics, received hydralazine (50 mg twice daily) for three months.
- Hemodynamic parameters were measured during upright submaximal exercise before and after treatment.
- Cardiac index, stroke volume, and arteriovenous oxygen difference were analyzed.
Main Results:
- Acute hydralazine administration increased cardiac index via enhanced stroke volume.
- Long-term hydralazine treatment further augmented cardiac index.
- Arteriovenous oxygen difference decreased significantly with long-term treatment, suggesting improved oxygen utilization or distribution.
Conclusions:
- Hydralazine exhibits distinct acute and long-term hemodynamic effects in CHF patients.
- Long-term hydralazine therapy may improve blood flow distribution, potentially favoring exercising muscles.
- The findings suggest a beneficial adaptation in circulatory response to hydralazine over time.
Abstract:
Nine male patients with stable chronic heart failure of different etiology and optimally treated with digoxine and diuretics were given hydralazine, 50 mg b.i.d., during three months. Hemodynamic parameters were evaluated during upright submaximal exercise. An increase in cardiac index due to an increased stroke volume was noted following the first dose of hydralazine. After three months' treatment, cardiac index was further increased. The arteriovenous oxygen difference was initially unchanged, but significantly decreased following long-term treatment. These findings may indicate different effects of hydralazine acutely and after long-term treatment. It is suggested that the initial increase in blood flow is directed mainly to regions other than the exercising muscles, while more blood is directed to the muscles after long-term treatment. A possible mechanism to explain this postulated difference is discussed.